Versican Plus DHPPi

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

klieb distemper virus, razza CDV Bio 11/A, klieb adenovirus tat-tip 2, razza CAV-2 Bio 13, klieb parvovirus tip 2b, razza CPV-2b Bio 12/B u l-klieb parainfluenza tat-tip 2 virus, razza CPiV-2 Bio 15 (kollha ħaj attenwat)

Available from:

Zoetis Belgium SA

ATC code:

QI07AD04

INN (International Name):

canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus

Therapeutic group:

Klieb

Therapeutic area:

Immunoloġiċi għall-canidae, vaċċini virali Ħajjin

Therapeutic indications:

Immunizzazzjoni attiva ta 'klieb minn sitt ġimgħat. biex tipprevjeni l-mortalità u sinjali kliniċi ikkawżati mill-klieb distemper virus,biex jimpedixxi l-mortalità u sinjali kliniċi ikkawżati mill-klieb adenovirus tat-tip 1,li jipprevjenu l-sinjali kliniċi u l-eskrezzjoni virali kkawżata mill-klieb adenovirus tat-tip 2,għall-prevenzjoni ta ' sinjali kliniċi, lewkopenija u l-eskrezzjoni virali kkawżata mill-klieb parvovirus,għall-prevenzjoni tal-sinjali kliniċi u l-eskrezzjoni virali kkawżata mill-klieb parainfluenza virus.

Product summary:

Revision: 7

Authorization status:

Awtorizzat

Authorization date:

2014-07-03

Patient Information leaflet

                                13
8.
ŻMIEN TA’ TIŻMIM
9.
TWISSIJIET SPEĊJALI OĦRA, JEKK MEĦTIEĠ
Aqra l-fuljett ta’ tagħrif qabel lużu.
10.
DATA TA’ SKADENZA
_ _
Jiskadi {xahar/sena}
Ladarba jitħallat uża fil-pront.
11.
KUNDIZZJONIJIET SPEĊJALI DWAR KIF GĦANDU JINĦAŻEN
Aħżen u ttrasporta ġo friġġ.
Tiffriżax.
Ipproteġi mid-dawl.
_ _
12.
PREKAWZJONIJIET SPEĊJALI DWAR IR-RIMI TA’ PRODOTTI MHUX UŻATI
JEW MATERJAL IEĦOR GĦAR-RIMI, JEKK IKUN IL-KAŻ
Rimi:
aqra l-fuljett ta’ tagħrif.
13.
IL-KLIEM “GĦALL-KURA TAL-ANNIMALI BISS” U KUNDIZZJONIJIET JEW
RESTRIZZJONIJIET DWAR IL-PROVVISTA U L-UŻU, JEKK APPLIKABBLI
Għall-kura tal-annimali
biss. Għandu jingħata biss b’riċetta veterinarja.
14.
IL-KLIEM “ŻOMM FEJN MA JIDHIRX U MA JINTLAĦAQX MIT-TFAL”
Żomm fejn ma jidhirx
u ma jintlaħaqx
mit-tfal.
15.
L-ISEM U L-INDIRIZZ TAD-
DETENTUR TAL-AWTORIZZAZZJONI GĦAT-
TQEGĦID FIS-SUQ
Zoetis Belgium
SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
IL-BELĠJU
16.
NUMRU/I TAL-AWTORIZZAZZJONI GĦAT-TQEGĦID FIS-SUQ
EU/2/14/169/001
EU/2/14/169/002
14
17.
NUMRU TAL-LOTT TAL-MANIFATTUR
Lott {numru}
15
TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ UNITAJIET ŻGĦAR TA’
IPPAKKJAR LI
JMISS MAL-PRODOTT
KUNJETT (LIJOFILIŻAT DOŻA WAĦDA)
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Versican Plus DHPPi – lijofiliżat - għall-klieb
2.
KWANTITÀ TAS-SUSTANZA(I) ATTIVA(I)
DHPPi
3.
KONTENUT BĦALA PIŻ, VOLUM JEW NUMRU TA’ DOŻI
Doża waħda
4.
MOD(I) TA’ AMMINISTRAZZJONI
SC
5.
ŻMIEN TA’ TIŻMIM
6.
NUMRU TAL-LOTT
_ _
Lott {numru}
7.
DATA TA’ SKADENZA
Jiskadi {xahar/sena}
8.
IL-KLIEM “GĦALL-KURA TAL-ANNIMALI BISS”
Għall-kura tal-annimali
biss.
16
TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ UNITAJIET ŻGĦAR TA’
IPPAKKJAR LI
JMISS MAL-PRODOTT
KUNJETT (SOLVENT 1 ML)
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Versican Plus DHPPi – solvent - għall-klieb
2.
KWANTITÀ TAS-SUSTANZA(I) ATTIVA(I)
_Aqua ad iniectabilia_
3.
KONTENUT BĦALA PIŻ, VOLUM JEW NUMRU TA’ DOŻI
1 ml
4.
MOD(I) TA’ AMMINISTRAZZJONI
SC
5.
ŻMIEN TA’ TIŻM
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Versican Plus DHPPi lijofiliżat u solvent għal sospensjoni
għall-injezzjoni
għall-klieb
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
Kull
doża ta’ 1 ml fiha:
SUSTANZI ATTIVI:
LIJOFILIŻAT (ATTENWAT ĦAJ):_ _
_ _
_ _
_ _
_ _
_ _
MINIMU
MASSIMU
Canine distemper virus, strejn CDV Bio 11/A
10
3.1
TCID
50
*
10
5.1
TCID
50
Canine adenovirus tip 2, strejn CAV-2-Bio 13
10
3.6
TCID
50
*
10
5.3
TCID
50
Canine parvovirus tip 2b, strejn CPV-2b-Bio 12/B
10
4.3
TCID
50
*
10
6.6
TCID
50
Canine parainfluenza virus tip 2, strejn CPiV-2-Bio 15
10
3.1
TCID
50
*
10
5.1
TCID
50
SOLVENT (INATTIVAT)
:
Ilma għall-injezzjonijiet
(
_Aqua ad iniectabilia_
)
1 ml
*
50% doża infettiva tat-tessut ikkultivat.
Għal-lista
sħiħa tal-ingredjenti
(mhux attivi), ara s-sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Lijofiliżat u solvent għal sospensjoni għall-injezzjoni.
Id-dehra viżiva hija kif ġejja:
Lijofiliżat:
materjal bħal sponża ta’ lewn bajdani.
Solvent: likwidu ċar bla kulur.
4.
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Klieb
4.2
INDIKAZZJONIJIET GĦAL UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT.
Tilqim
attiv għall-klieb
minn età ta’ 6 ġimgħat:
-
biex tilqa’ għal mortalità u sinjali kliniċi
kkawżati mill-canine
distemper virus,
-
biex tilqa’
għal mortalità u sinjali kliniċi
kkawżati mill-canine adenovirus tip 1,
-
biex tilqa’
għas-sinjali kliniċi
u tixrid
virali
kkawżati mill-canine adenovirus tip 2,
-
biex tilqa’ għas-sinjali kliniċi,
lewkopinja
u tixrid
virali
kkawżati mill-canine
parvo virus, u
-
biex tilqa’
għas-sinjali kliniċi
(tnixxija
mill-imnieħer
u l-għajnejn) u tnaqqas it-tixrid
virali
kkawżati mill-canine parainfluenza virus.
Bidu tal-immunità:
-
3 ġimgħat wara l-ewwel tilqima
għal CDV, CAV, CPV, u
-
3 ġimgħat
wara li jintemm
il-kors primarju għal CpiV.
3
Tul tal-immunità:
Tal-anqas tliet snin wara l-kors ta’ tilqim
primarju g
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-05-2019
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-05-2019
Public Assessment Report Public Assessment Report Bulgarian 27-04-2015
Patient Information leaflet Patient Information leaflet Spanish 16-05-2019
Public Assessment Report Public Assessment Report Spanish 27-04-2015
Patient Information leaflet Patient Information leaflet Czech 16-05-2019
Public Assessment Report Public Assessment Report Czech 27-04-2015
Patient Information leaflet Patient Information leaflet Danish 16-05-2019
Public Assessment Report Public Assessment Report Danish 27-04-2015
Patient Information leaflet Patient Information leaflet German 16-05-2019
Public Assessment Report Public Assessment Report German 27-04-2015
Patient Information leaflet Patient Information leaflet Estonian 16-05-2019
Public Assessment Report Public Assessment Report Estonian 27-04-2015
Patient Information leaflet Patient Information leaflet Greek 16-05-2019
Public Assessment Report Public Assessment Report Greek 27-04-2015
Patient Information leaflet Patient Information leaflet English 16-05-2019
Public Assessment Report Public Assessment Report English 27-04-2015
Patient Information leaflet Patient Information leaflet French 16-05-2019
Public Assessment Report Public Assessment Report French 27-04-2015
Patient Information leaflet Patient Information leaflet Italian 16-05-2019
Public Assessment Report Public Assessment Report Italian 27-04-2015
Patient Information leaflet Patient Information leaflet Latvian 16-05-2019
Public Assessment Report Public Assessment Report Latvian 27-04-2015
Patient Information leaflet Patient Information leaflet Lithuanian 16-05-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-05-2019
Public Assessment Report Public Assessment Report Lithuanian 27-04-2015
Patient Information leaflet Patient Information leaflet Hungarian 16-05-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 16-05-2019
Public Assessment Report Public Assessment Report Hungarian 27-04-2015
Patient Information leaflet Patient Information leaflet Dutch 16-05-2019
Public Assessment Report Public Assessment Report Dutch 27-04-2015
Patient Information leaflet Patient Information leaflet Polish 16-05-2019
Public Assessment Report Public Assessment Report Polish 27-04-2015
Patient Information leaflet Patient Information leaflet Portuguese 16-05-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 16-05-2019
Public Assessment Report Public Assessment Report Portuguese 27-04-2015
Patient Information leaflet Patient Information leaflet Romanian 16-05-2019
Public Assessment Report Public Assessment Report Romanian 27-04-2015
Patient Information leaflet Patient Information leaflet Slovak 16-05-2019
Public Assessment Report Public Assessment Report Slovak 27-04-2015
Patient Information leaflet Patient Information leaflet Slovenian 16-05-2019
Summary of Product characteristics Summary of Product characteristics Slovenian 16-05-2019
Public Assessment Report Public Assessment Report Slovenian 27-04-2015
Patient Information leaflet Patient Information leaflet Finnish 16-05-2019
Public Assessment Report Public Assessment Report Finnish 27-04-2015
Patient Information leaflet Patient Information leaflet Swedish 16-05-2019
Public Assessment Report Public Assessment Report Swedish 27-04-2015
Patient Information leaflet Patient Information leaflet Norwegian 16-05-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 16-05-2019
Patient Information leaflet Patient Information leaflet Icelandic 16-05-2019
Summary of Product characteristics Summary of Product characteristics Icelandic 16-05-2019
Patient Information leaflet Patient Information leaflet Croatian 16-05-2019
Public Assessment Report Public Assessment Report Croatian 27-04-2015